EZH2 Promotes Malignant Behaviors via Cell Cycle Dysregulation and Its mRNA Level Associates with Prognosis of Patient with Non-Small Cell Lung Cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EZH2 Promotes Malignant Behaviors via Cell Cycle Dysregulation and Its mRNA Level Associates with Prognosis of Patient with Non-Small Cell Lung Cancer
Authors
Keywords
Non-small cell lung cancer, Small interfering RNAs, Lung and intrathoracic tumors, Secondary lung tumors, Cell cycle and cell division, Adenocarcinoma of the lung, Cell staining, Transfection
Journal
PLoS One
Volume 7, Issue 12, Pages e52984
Publisher
Public Library of Science (PLoS)
Online
2013-01-01
DOI
10.1371/journal.pone.0052984
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer treatment and survivorship statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis
- (2012) Paul Delgado-Olguín et al. NATURE GENETICS
- Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
- (2012) Panagiotis Ntziachristos et al. NATURE MEDICINE
- Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma
- (2011) Wei Cao et al. CANCER
- Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer
- (2011) Huqun et al. CANCER
- EZH2 Promotes Malignant Phenotypes and Is a Predictor of Oral Cancer Development in Patients with Oral Leukoplakia
- (2011) W. Cao et al. Cancer Prevention Research
- Genetic and epigenetic changes in lung carcinoma and their clinical implications
- (2011) Jing Wen et al. MODERN PATHOLOGY
- Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
- (2011) Francesco Crea et al. Molecular Cancer
- EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression
- (2011) T. Fan et al. MOLECULAR CANCER RESEARCH
- Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer
- (2010) JUNG HYE CHOI et al. APMIS
- Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance
- (2010) Junko Kikuchi et al. CANCER
- Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma
- (2010) Adam D. Toll et al. HUMAN PATHOLOGY
- The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells
- (2010) Ryutaro Aoki et al. JOURNAL OF HEPATOLOGY
- Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early-Stage Non-small Cell Lung Cancer
- (2010) Ana Belén Custodio et al. Journal of Thoracic Oncology
- An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB
- (2010) Junxia Min et al. NATURE MEDICINE
- Targeted Overexpression of EZH2 in the Mammary Gland Disrupts Ductal Morphogenesis and Causes Epithelial Hyperplasia
- (2009) Xin Li et al. AMERICAN JOURNAL OF PATHOLOGY
- Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
- (2009) W. Fiskus et al. BLOOD
- Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
- (2009) Ø Fluge et al. BRITISH JOURNAL OF CANCER
- EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance
- (2009) M.-L. Suva et al. CANCER RESEARCH
- Expression Profile of the Polycomb Group Protein Enhancer of Zeste Homologue 2 and its Prognostic Relevance in Renal Cell Carcinoma
- (2009) Stefan Hinz et al. JOURNAL OF UROLOGY
- Polycomb Group Protein Enhancer of Zeste 2 Is an Oncogene That Promotes the Neoplastic Transformation of a Benign Prostatic Epithelial Cell Line
- (2009) B. D.W. Karanikolas et al. MOLECULAR CANCER RESEARCH
- Mir-214-Dependent Regulation of the Polycomb Protein Ezh2 in Skeletal Muscle and Embryonic Stem Cells
- (2009) Aster H. Juan et al. MOLECULAR CELL
- Linking DNA methylation and histone modification: patterns and paradigms
- (2009) Howard Cedar et al. NATURE REVIEWS GENETICS
- Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells
- (2008) Hideo Watanabe et al. Cancer Cell International
- The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma
- (2008) Motoko Sasaki et al. LABORATORY INVESTIGATION
- SWI/SNF Mediates Polycomb Eviction and Epigenetic Reprogramming of the INK4b-ARF-INK4a Locus
- (2008) S. K. Kia et al. MOLECULAR AND CELLULAR BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started